Related references
Note: Only part of the references are listed.Cost-Effectiveness Analysis of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Thai Patients With Non-Valvular Atrial Fibrillation
Piyameth Dilokthornsakul et al.
HEART LUNG AND CIRCULATION (2020)
Anticoagulants for Stroke Prevention in Atrial Fibrillation in Elderly Patients
Andreas Schaefer et al.
CARDIOVASCULAR DRUGS AND THERAPY (2020)
Updating the Cost Effectiveness of Oral Anticoagulants for Patients with Atrial Fibrillation Based on Varying Stroke and Bleed Risk Profiles
Ching-Yu Wang et al.
PHARMACOECONOMICS (2020)
Direct Oral Anticoagulants vs. Vitamin-K Antagonists in the Elderly With Atrial Fibrillation: A Systematic Review Comparing Benefits and Harms Between Observational Studies and Randomized Controlled Trials
Nan-Nan Shen et al.
FRONTIERS IN CARDIOVASCULAR MEDICINE (2020)
Comparison of real-world outcomes in patients with nonvalvular atrial fibrillation treated with direct oral anticoagulant agents or warfarin
Manasi Datar et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2019)
Resource Use and Burden of Hospitalization, Outpatient, Physician, and Drug Costs in Short- and Long-term Care After Acute Myocardial Infarction
Dat T. Tran et al.
CANADIAN JOURNAL OF CARDIOLOGY (2018)
The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
Jan Steffel et al.
EUROPEAN HEART JOURNAL (2018)
Different safety profiles of oral anticoagulants in very elderly non-valvular atrial fibrillation patients. A retrospective propensity score matched cohort study
Giacomo Zoppellaro et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2018)
Stroke Prevention in Nonvalvular Atrial Fibrillation A Stakeholder Perspective
Mohamad Alkhouli et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
A Propensity Score Matched Comparison of Clinical Outcomes in Atrial Fibrillation Patients Taking Vitamin K Antagonists: Comparing the Real-World vs Clinical Trials
Jose Miguel Rivera-Caravaca et al.
MAYO CLINIC PROCEEDINGS (2018)
Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation at high risk of bleeding and normal kidney function
Inmaculada Hernandez et al.
THROMBOSIS RESEARCH (2017)
Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis
Jose A. Lopez-Lopez et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis
Jose A. Lopez-Lopez et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
Cost-effectiveness modelling of novel oral anticoagulants incorporating real-world elderly patients with atrial fibrillation
Ying Jiao Zhao et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2016)
Incidence and Determinants of Traumatic Intracranial Bleeding Among Older Veterans Receiving Warfarin for Atrial Fibrillation
John A. Dodson et al.
JAMA CARDIOLOGY (2016)
Impacts of Patent Expiry on Daily Cost of Pharmaceutical Treatments in Eight OECD Countries, 2004-2010
Ernst R. Berndt et al.
INTERNATIONAL JOURNAL OF THE ECONOMICS OF BUSINESS (2016)
Cost-effectiveness of Dabigatran and Rivaroxaban Compared with Warfarin for Stroke Prevention in Patients with Atrial Fibrillation
Ye Wang et al.
CARDIOVASCULAR DRUGS AND THERAPY (2014)
Cost-Effectiveness of Apixaban Versus Other New Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation
Gregory Y. H. Lip et al.
CLINICAL THERAPEUTICS (2014)
ESTIMATING THE INPATIENT AND OUTPATIENT COSTS OF ATRIAL FIBRILLATION AND ASSOCIATED ADVERSE EVENTS
S. H. Forrester et al.
VALUE IN HEALTH (2014)
Concerns About the Use of New Oral Anticoagulants for Stroke Prevention in Elderly Patients with Atrial Fibrillation
Claudia Stoellberger et al.
DRUGS & AGING (2013)
Atrial fibrillation: Profile and burden of an evolving epidemic in the 21st century
Jocasta Ball et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2013)
The Global Burden of Atrial Fibrillation and Stroke A Systematic Review of the Epidemiology of Atrial Fibrillation in Regions Outside North America and Europe
Gregory Y. H. Lip et al.
CHEST (2012)
Cost-Utility of Aspirin and Proton Pump Inhibitors for Primary Prevention
Stephanie R. Earnshaw et al.
ARCHIVES OF INTERNAL MEDICINE (2011)
Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses
Joshua Pink et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Treatments for stroke prevention in atrial fibrillation: A network meta-analysis and indirect comparisons versus dabigatran etexilate
Neil S. Roskell et al.
THROMBOSIS AND HAEMOSTASIS (2010)
Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold
Scott D Grosse
Expert Review of Pharmacoeconomics & Outcomes Research (2008)
A meta-analysis of quality-of-life estimates for stroke
TO Tengs et al.
PHARMACOECONOMICS (2003)
Share Paper
